Pub Date : 2020-04-01DOI: 10.6004/jadpro.2020.11.3.21
{"title":"The Advanced Practitioner’s Role in Treating Older Adults With Hematologic Malignancies","authors":"","doi":"10.6004/jadpro.2020.11.3.21","DOIUrl":"https://doi.org/10.6004/jadpro.2020.11.3.21","url":null,"abstract":"","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"114 35","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141217513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-01DOI: 10.6004/jadpro.2020.11.3.24
P. Viale
{"title":"ASH Highlights and Commentary: Multiple Myeloma","authors":"P. Viale","doi":"10.6004/jadpro.2020.11.3.24","DOIUrl":"https://doi.org/10.6004/jadpro.2020.11.3.24","url":null,"abstract":"","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45419115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-01DOI: 10.6004/jadpro.2019.10.8.11
Karen Schiavo, ARNP, AOCNP
{"title":"Responding to the Evolving Treatment Paradigm for Myelofibrosis: Narratives on Collaboration","authors":"Karen Schiavo, ARNP, AOCNP","doi":"10.6004/jadpro.2019.10.8.11","DOIUrl":"https://doi.org/10.6004/jadpro.2019.10.8.11","url":null,"abstract":"","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41459798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-01DOI: 10.6004/iadpro.2019.10.8.11
Karen Schiavo, Arnp, Aocnp
{"title":"Responding to the Evolving Treatment Paradigm for Myelofibrosis: Narratives on Collaboration","authors":"Karen Schiavo, Arnp, Aocnp","doi":"10.6004/iadpro.2019.10.8.11","DOIUrl":"https://doi.org/10.6004/iadpro.2019.10.8.11","url":null,"abstract":"","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42064890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-11-01DOI: 10.6004/jadpro.2019.10.8.12
Nancy M. Nix, Allyson Price
Abstract Acute myeloid leukemia is the most common form of acute leukemia in adults. In recent years, there has been robust characterization of molecular targets for drug development, leading to the U.S. Food & Drug Administration approval of numerous new treatments during 2017 and 2018. In light of these new approvals, this article provides an update for advanced practitioners on risk stratification, which is critical for guiding treatment selection.
{"title":"Acute Myeloid Leukemia: An Ever-Changing Disease","authors":"Nancy M. Nix, Allyson Price","doi":"10.6004/jadpro.2019.10.8.12","DOIUrl":"https://doi.org/10.6004/jadpro.2019.10.8.12","url":null,"abstract":"Abstract Acute myeloid leukemia is the most common form of acute leukemia in adults. In recent years, there has been robust characterization of molecular targets for drug development, leading to the U.S. Food & Drug Administration approval of numerous new treatments during 2017 and 2018. In light of these new approvals, this article provides an update for advanced practitioners on risk stratification, which is critical for guiding treatment selection.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"10 1","pages":"4 - 8"},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43056867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-01DOI: 10.6004/JADPRO.2019.10.5.9
Marianne J. Davies, DNP, CNS, ACNP, AOCNP, Kristen Crowley, MSN, APRN
{"title":"Narratives on Collaboration: Optimizing Management of Immune-Related Adverse Events","authors":"Marianne J. Davies, DNP, CNS, ACNP, AOCNP, Kristen Crowley, MSN, APRN","doi":"10.6004/JADPRO.2019.10.5.9","DOIUrl":"https://doi.org/10.6004/JADPRO.2019.10.5.9","url":null,"abstract":"","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45462370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-01DOI: 10.6004/jadpro.2019.10.4.9
M. Alencar
Chimeric antigen receptor (CAR) T-cell therapy represents an exciting innovation in the treatment of cancer. With the approval of two revolutionary anti-CD19 CAR T-cell therapies (axicabtagene ciloleucel [Yescarta] and tisagenlecleucel [Kymriah]) for relapsed/refractory large B-cell lymphoma, health-care providers must consider how to prepare for the future of cancer care. While these therapies have been shown to provide clinical benefit to many patients, they are associated with a range of adverse events (AEs) that will need to be identified, assessed, and managed. Widespread education of health-care providers, patients, and caregivers will also be essential to ensure the success of this novel treatment. This supplement aims to provide practical information to the advanced practitioner on a number of considerations relating to the implementation and expansion of CAR T-cell therapy, including CAR T-cell biology and mechanism of action, how to identify, grade, and manage treatment-related AEs, as well as best practices for educating patients and caregivers about this type of therapy.
嵌合抗原受体（CAR）T细胞疗法是癌症治疗中一项令人兴奋的创新。随着两种针对复发/难治性大B细胞淋巴瘤的革命性抗CD19 CAR T细胞疗法（axcabtagene ciloleucel[Yescarta]和tisagenleleucel[Kymriah]）的批准，医疗保健提供者必须考虑如何为癌症治疗的未来做好准备。虽然这些疗法已被证明为许多患者提供了临床益处，但它们与一系列不良事件（AE）有关，需要进行识别、评估和管理。对医疗保健提供者、患者和护理人员进行广泛的教育对于确保这种新型治疗的成功也至关重要。本补充旨在向高级从业者提供与CAR T细胞治疗的实施和扩展相关的一些考虑因素的实用信息，包括CAR T淋巴细胞生物学和作用机制，如何识别、分级和管理治疗相关AE，以及教育患者和护理人员了解这类治疗的最佳实践。
{"title":"CAR T-Cell Therapy for Large B-Cell Lymphoma","authors":"M. Alencar","doi":"10.6004/jadpro.2019.10.4.9","DOIUrl":"https://doi.org/10.6004/jadpro.2019.10.4.9","url":null,"abstract":"Chimeric antigen receptor (CAR) T-cell therapy represents an exciting innovation in the treatment of cancer. With the approval of two revolutionary anti-CD19 CAR T-cell therapies (axicabtagene ciloleucel [Yescarta] and tisagenlecleucel [Kymriah]) for relapsed/refractory large B-cell lymphoma, health-care providers must consider how to prepare for the future of cancer care. While these therapies have been shown to provide clinical benefit to many patients, they are associated with a range of adverse events (AEs) that will need to be identified, assessed, and managed. Widespread education of health-care providers, patients, and caregivers will also be essential to ensure the success of this novel treatment. This supplement aims to provide practical information to the advanced practitioner on a number of considerations relating to the implementation and expansion of CAR T-cell therapy, including CAR T-cell biology and mechanism of action, how to identify, grade, and manage treatment-related AEs, as well as best practices for educating patients and caregivers about this type of therapy.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"10 1","pages":"5 - 9"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47327888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-04-01DOI: 10.6004/jadpro.2019.10.3.6
{"title":"Advances in the Treatment of HER2-Positive Breast Cancer","authors":"","doi":"10.6004/jadpro.2019.10.3.6","DOIUrl":"https://doi.org/10.6004/jadpro.2019.10.3.6","url":null,"abstract":"","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43421584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-04-01DOI: 10.6004/JADPRO.2019.10.3.3
P. Kiel, Pharmd, Bcps, Bcop
{"title":"2017-2018 Drug Approvals in Solid Tumors","authors":"P. Kiel, Pharmd, Bcps, Bcop","doi":"10.6004/JADPRO.2019.10.3.3","DOIUrl":"https://doi.org/10.6004/JADPRO.2019.10.3.3","url":null,"abstract":"","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46394069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-04-01DOI: 10.6004/jadpro.2019.10.3.7
{"title":"Surgical Implications for Women With Breast Cancer","authors":"","doi":"10.6004/jadpro.2019.10.3.7","DOIUrl":"https://doi.org/10.6004/jadpro.2019.10.3.7","url":null,"abstract":"","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46408594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：